Endovia Health Sciences, Inc. — Form 8-K
Filed October 27, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 72/100
What the filing says
Endovia Health Sciences amended its September 2025 Securities Purchase Agreement with C/M Capital Master Fund, LP on October 22, 2026, increasing the total maximum commitment amount from $35 million to $135 million (adding $100 million in new commitment). The addendum allows C/M Capital to purchase additional common shares beyond the initial 10.875 million shares already issued, subject to fixed purchase prices at 95% of prior-day VWAP, daily caps ($500K fixed purchases, $2M VWAP purchases), and a 19.99% exchange cap unless prices meet specific thresholds or stockholder approval is obtained.
Why this rating
Material financing expansion (15x company market cap) provides crucial liquidity runway for microcap; neutral because execution uncertain and heavily dilutive to existing shareholders if fully drawn.
Price action (we called it neutral)
before filing · preread $0.17 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 27, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.